Form 4: Assembly Biosciences' Chief Medical Officer Granted Stock Options

Anuj Gaggar, Chief Medical Officer of Assembly Biosciences, was granted stock options on March 29, 2025, according to a Form 4 filing.

Summary

• Anuj Gaggar, the Chief Medical Officer of Assembly Biosciences, Inc., received stock options on March 29, 2025.
• The options grant totals 24,200 shares with an exercise price of $10.62.
• The options vest over four years: 25% vests on March 29, 2026, and the remaining 75% vests in 36 monthly installments, becoming fully vested on March 29, 2029.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Gilead Sciences, Amgen, and Biogen routinely use stock options to attract and retain talent.
• The vesting schedule of Assembly Biosciences' options is typical, with a four-year vesting period being common.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Assembly Biosciences, Anuj Gaggar, Chief Medical Officer, vesting